SCHEMBL4257154

SCHEMBL4257154

O=C(O)CN1CCC(=C(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SETD7 Q8WTS6 1/20 0.56
OPRD1 P41143 6/20 0.51
OPRK1 P41145 5/20 0.51
OPRM1 P35372 4/20 0.51
FNTA P49354 1/20 0.50
FNTB P49356 1/20 0.50
HTR2A P28223 2/20 0.47
HTR2B P41595 2/20 0.47
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
HTR2C P28335 1/20 0.47
P2RX7 Q99572 1/20 0.47
HTR7 P34969 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.43
CHRM2 P08172 1/20 0.43
CYP2D6 P10635 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
HRH1 P35367 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11033270 0.91 SLC6A9 (0.49) SETD7OPRD1OPRK1OPRM1FNTA
SCHEMBL11036336 0.87 SETD7 (0.53) SETD7OPRD1OPRK1OPRM1FNTA
SCHEMBL14198340 0.83 SETD7 (0.57) SETD7OPRD1OPRK1OPRM1FNTA
SCHEMBL14282966 0.81 OPRD1 (0.60) SETD7OPRD1OPRK1OPRM1FNTA
SCHEMBL14282904 0.81 OPRD1 (0.50) SETD7OPRD1OPRK1OPRM1FNTA
SCHEMBL11099482 0.79 DRD2 (0.48) SETD7OPRD1OPRK1OPRM1FNTA
SCHEMBL14282965 0.79 NPC1 (0.56) SETD7OPRD1OPRK1OPRM1ALDH1A1
SCHEMBL14198385 0.79 SETD7 (0.65) SETD7OPRD1OPRK1OPRM1FNTA
SCHEMBL10748250 0.79 SETD7 (0.59) SETD7OPRD1OPRK1OPRM1FNTA
Hydrochloric Acid SCHEMBL11035720 0.78 DRD2 (0.47) SETD7OPRD1OPRK1OPRM1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0048705-B1 2-(4-(DIPHENYLMETHYLENE)-1-PIPERIDINYL)-ACETIC ACIDS AND THEIR AMIDES, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM U C B, S.A. (BE) 1984-07-11 EP claimed
JP-57082369-A None JP disclosed
EP-1742707-A4 TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS HYPNION INC (US) 2009-08-05 EP disclosed
US-7355042-B2 Treatment of CNS disorders using CNS target modulators HYPNION, INC. (US) 2008-04-08 US disclosed
EP-1443929-A4 TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS HYPNION INC (US) 2008-02-06 EP disclosed
US-7317026-B2 Sleep disorders; side effect reduction ; antihistamine antagonist HYPNION, INC. (US) 2008-01-08 US disclosed
US-7317026-B2 Sleep disorders; side effect reduction ; antihistamine antagonist HYPNION, INC. (US) 2008-01-08 US disclosed
US-7317026-B2 Sleep disorders; side effect reduction ; antihistamine antagonist HYPNION, INC. (US) 2008-01-08 US disclosed
US-7189757-B2 Treatment of sleep disorders using CNS target modulators HYPNION, INC. (US) 2007-03-13 US disclosed
US-7189757-B2 Treatment of sleep disorders using CNS target modulators HYPNION, INC. (US) 2007-03-13 US disclosed
EP-1443929-A2 TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS Hypnion, Inc. (US) 2004-08-11 EP disclosed
US-20040142972-A1 CNS target modulators HYPNION, INC. 2004-07-22 US disclosed
US-20030187021-A1 Treatment of CNS disorders using CNS target modulators HYPNION, INC. 2003-10-02 US disclosed
WO-2003032912-A2 TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS HYPNION, INC. (US) 2003-04-24 WO disclosed
EP-0048705-B1 2-(4-(DIPHENYLMETHYLENE)-1-PIPERIDINYL)-ACETIC ACIDS AND THEIR AMIDES, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM U C B, S.A. (BE) 1984-07-11 EP disclosed
US-4443460-A ANTIALLERGENS, ANTIHISTAMINES, ANTISPASMODICS, BRONCHODILATORS UCB, SOCIETE ANONYME (BE) 1984-04-17 US disclosed
US-4443460-A ANTIALLERGENS, ANTIHISTAMINES, ANTISPASMODICS, BRONCHODILATORS UCB, SOCIETE ANONYME (BE) 1984-04-17 US disclosed
US-4443460-A ANTIALLERGENS, ANTIHISTAMINES, ANTISPASMODICS, BRONCHODILATORS UCB, SOCIETE ANONYME (BE) 1984-04-17 US disclosed
JP-S5782369-A 2-(4-(DIPHENYLMETHYLENE)-1-PIPERIDINYL)-ACETIC ACID AND ITS AMIDE, ITS NONTOXIC SALT AVAILABLE AS MEDICINE AND ITS MANUFACTURE UCB SA 1982-05-22 JP disclosed
EP-0048705-A1 2-(4-(Diphenylmethylene)-1-piperidinyl)-acetic acids and their amides, their preparation and pharmaceutical preparations containing them U C B, S.A. (BE) 1982-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187021-A1 Treatment of CNS disorders using CNS target modulators HCRTR2, CNR2, CNR1 SETD7 1332/4885OPRD1 645/4885OPRK1 380/4885
US-20040142972-A1 CNS target modulators HCRTR2, CNR2, CNR1 SETD7 1434/4885OPRD1 399/4885OPRK1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.